Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses the role of neoadjuvant chemotherapy and the impact of the latest randomized trials in bladder cancer at ASCO GU 2016
Advertisement
[the_ad id="32629"]
Annual Meeting GU 2016 Role of neoadjuvant chemotherapy and the impact of the latest randomized trials in bladder cancer
By Editor